Natalia Bien
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Natalia Bien has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Lesiak
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Pomorska Street 251, 92-213 Lodz, Poland
2 shared publications - Joanna Narbutt
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Pomorska Street 251, 92-213 Lodz, Poland
2 shared publications - Dorota Sobolewska-Sztychny
Department of Dermatology, Pediatric Dermatology and Dermatological Oncology, Medical University of Lodz, Pomorska Street 251, 92-213 Lodz, Poland
1 shared publication - Magdalena Ciążyńska
Department of Dermatology, Paediatric Dermatology and Dermatological Oncology, Medical University of Lodz, 90-419 Lodz, Poland
1 shared publication - Maria Markowska
Department of Infectious, Tropical and Parasitic Diseases for Children, Władysław Biegański Voivodeship Specialist Hospital, Gen. Karola Kniaziewicza Street 1/5, 91-347 Lodz, Poland
1 shared publication - Maria Rajczak
Department of Dermatology, Pediatric Dermatology and Oncology, Medical University of Lodz, Pomorska Street 251, 92-213 Lodz, Poland
1 shared publication
Latest Publications
- Open Access
- 2 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (3) , 1138
Primary Cutaneous B-Cell Lymphoma Imitating Pyoderma Gangrenosum: A Rare and Complex Diagnostic Challenge
Background: Primary cutaneous B-cell lymphomas (CBCLs) are a rare and heterogeneous group of lymphomas, among which the anaplastic variant of diffuse large B-cell lymphoma (A-DLBCL) represents an exceptionally rare entity. Although they typically present as painless and non-ulcerated skin lesions, rare variants may exhibit atypical clinical features. Pyoderma gangrenosum (PG) is a rare inflammatory ulcerative disease that may overlap clinically with other ulcerative dermatoses and pose diagnostic challenges due to the absence of standardized differential algorithms. Methods: An 85-year-old male presented with multiple rapidly progressive, painful, ulcerative lesions, initially misdiagnosed as PG and treated with oral cyclosporine with no clinical response. Skin biopsy specimens underwent detailed histopathological and immunohistochemical evaluation. Results: The analyses revealed dense infiltration of atypical large lymphoid cells, with CD20, CD45, and CD30 positivity, and a Ki-67 proliferation index of approximately 90%, consistent with primary cutaneous A-DLBCL. Owing to the delayed correct diagnosis, the patient’s condition deteriorated rapidly, leading to his death before appropriate therapy could be initiated. Conclusions: The case documents an exceptionally rare cutaneous presentation of A-DLBCL, expanding the extremely limited literature on this enigmatic entity. Furthermore, it underscores the fundamental role of early skin biopsy in the differential diagnosis of non-specific ulcerative lesions, which is critical for ensuring appropriate treatment administration within the therapeutic window in cases of malignancy.
- 2 February 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (3) , 1138
Open AccessPrimary Cutaneous B-Cell Lymphoma Imitating Pyoderma Gangrenosum: A Rare and Complex Diagnostic Challenge
Background: Primary cutaneous B-cell lymphomas (CBCLs) are a rare and heterogeneous group of lymphomas, among which the anaplastic variant of diffuse large B-cell lymphoma (A-DLBCL) represents an exceptionally rare entity. Although they typically present as painless and non-ulcerated skin lesions, rare variants may exhibit atypical clinical features. Pyoderma gangrenosum (PG) is a rare inflammatory ulcerative disease that may overlap clinically with other ulcerative dermatoses and pose diagnostic challenges due to the absence of standardized differential algorithms. Methods: An 85-year-old male presented with multiple rapidly progressive, painful, ulcerative lesions, initially misdiagnosed as PG and treated with oral cyclosporine with no clinical response. Skin biopsy specimens underwent detailed histopathological and immunohistochemical evaluation. Results: The analyses revealed dense infiltration of atypical large lymphoid cells, with CD20, CD45, and CD30 positivity, and a Ki-67 proliferation index of approximately 90%, consistent with primary cutaneous A-DLBCL. Owing to the delayed correct diagnosis, the patient’s condition deteriorated rapidly, leading to his death before appropriate therapy could be initiated. Conclusions: The case documents an exceptionally rare cutaneous presentation of A-DLBCL, expanding the extremely limited literature on this enigmatic entity. Furthermore, it underscores the fundamental role of early skin biopsy in the differential diagnosis of non-specific ulcerative lesions, which is critical for ensuring appropriate treatment administration within the therapeutic window in cases of malignancy.
- Open Access
- 9 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6592
Gene Therapies in Dermatological Diseases: A Breakthrough in Treatment
Gene therapy involves introducing genetic material into cells to treat or prevent disease and offers highly targeted and potentially curative approaches for both inherited and acquired conditions. The skin is an especially suitable organ for gene therapy due to its accessibility, ease of sampling, rapid cell turnover, and the possibility for localized treatment with minimal systemic exposure. Gene therapy is being actively explored across a range of dermatological conditions, including recessive dystrophic epidermolysis bullosa, ichthyosis, psoriasis, chronic wounds, and melanoma, with therapeutic strategies encompassing viral vectors, non-viral delivery systems, gene editing technologies, RNA-based treatments, and cell-based approaches. These diverse methods aim to correct genetic defects, modulate immune responses, promote tissue repair, or selectively target malignant cells. This review examines the advancements and potential of gene therapies in addressing complex skin diseases, providing hope for improved patient outcomes and long-term care.
- 9 July 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (14) , 6592
Open AccessGene Therapies in Dermatological Diseases: A Breakthrough in Treatment
Gene therapy involves introducing genetic material into cells to treat or prevent disease and offers highly targeted and potentially curative approaches for both inherited and acquired conditions. The skin is an especially suitable organ for gene therapy due to its accessibility, ease of sampling, rapid cell turnover, and the possibility for localized treatment with minimal systemic exposure. Gene therapy is being actively explored across a range of dermatological conditions, including recessive dystrophic epidermolysis bullosa, ichthyosis, psoriasis, chronic wounds, and melanoma, with therapeutic strategies encompassing viral vectors, non-viral delivery systems, gene editing technologies, RNA-based treatments, and cell-based approaches. These diverse methods aim to correct genetic defects, modulate immune responses, promote tissue repair, or selectively target malignant cells. This review examines the advancements and potential of gene therapies in addressing complex skin diseases, providing hope for improved patient outcomes and long-term care.